About
Sam Ruta leads commercial strategy at DirectSeq, focusing on market growth and client engagement for RNA therapeutic solutions. With a background in biotech business development, Sam has driven partnerships that positioned DirectSeq as a leader in molecular analytics for RNA therapeutics.
As a forward-thinking executive with over two decades of dynamic experience in the healthcare space . I bring a proven track record in sales and business development. My creative and highly technical sales mindset fuels a passion for sales and overall organizational success. The end result is red carpet service for Physicians and patient care. Recognized for assembling high-performing teams, I lead them to surpass sales and business growth targets consistently.
Key Strengths
- Strategic Vision: Proven ability to identify and capitalize on emerging trends within the sales and diagnostics landscape.
- Relationship Management: Deep focus on cultivating strong client relationships by understanding unique needs and delivering tailored solutions, resulting in high client satisfaction and long-term retention.
- Business Expansion: Expertise in uncovering new business opportunities, forming strategic partnerships, and identifying sustainable revenue streams through market analysis and competitive intelligence.
Notable Achievements
- Innovative Growth: Led expansion into Pharmacogenetic (PGx), Cancer Genetic (CGx), and Next-Generation Sequencing (NGS) testing, diversifying Alliance Dx–Tesis service offerings and generating $30 million in new client revenue.
- Network Expansion: Secured commitments from 100 new physicians across GI, GU, and Hematology/Oncology specialties, resulting in a sustained $40 million annual run rate.
- Strategic Collaboration: Spearheaded the formation of GenPath and Pathline through collaboration with BioReference Laboratories and Orange Pathology Associates.